Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients’ Plasma by a Novel LC–MS/MS Method

The new breakthrough cystic fibrosis (CF) drug combination of ivacaftor (IVA), tezacaftor (TEZ), and elexacaftor (ELX), namely “caftor” drugs, directly modulates the activity and trafficking of the defective CF transmembrane conductance regulator protein (CFTR) underlying the CF disease. The role of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pigliasco, Federica, Cafaro, Alessia, Stella, Manuela, Baiardi, Giammarco, Barco, Sebastiano, Pedemonte, Nicoletta, D’Orsi, Claudia, Cresta, Federico, Casciaro, Rosaria, Castellani, Carlo, Calevo, Maria Grazia, Mattioli, Francesca, Cangemi, Giuliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953078/
https://www.ncbi.nlm.nih.gov/pubmed/36831163
http://dx.doi.org/10.3390/biomedicines11020628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953078/
https://www.ncbi.nlm.nih.gov/pubmed/36831163
http://dx.doi.org/10.3390/biomedicines11020628

Ejemplares similares